Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2022 March 22, 2022 argenx announces launch of proposed global offering March 22, 2022 argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis March 3, 2022 argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update February 28, 2022 argenx to Present at the 42nd Annual Cowen Health Care Conference February 24, 2022 argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022 February 10, 2022 argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference January 20, 2022 argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis January 7, 2022 argenx Highlights Strategic Priorities for 2022 January 3, 2022 argenx to Present at 40th Annual J.P. Morgan Healthcare Conference 2021 December 17, 2021 argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis November 10, 2021 argenx to Present at Upcoming Investor Conferences October 28, 2021 argenx Reports Third Quarter 2021 Financial Results and Provides Business Update Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
